-
1
-
-
84898663074
-
Annual report on status of cancer in China, 2010
-
Chen, W. et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 26, 48-58 (2014).
-
(2014)
Chin J Cancer Res.
, vol.26
, pp. 48-58
-
-
Chen, W.1
-
2
-
-
84897426270
-
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer
-
Lorusso, D., Petrelli, F., Coinu, A., Raspagliesi, F. & Barni, S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 133, 117-123 (2014).
-
(2014)
Gynecol Oncol.
, vol.133
, pp. 117-123
-
-
Lorusso, D.1
Petrelli, F.2
Coinu, A.3
Raspagliesi, F.4
Barni, S.5
-
3
-
-
84899992665
-
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial
-
Andre, F. et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 580-591 (2014).
-
(2014)
Lancet Oncol.
, vol.15
, pp. 580-591
-
-
Andre, F.1
-
4
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
Hess, G. et al. Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 27, 3822-3829 (2009).
-
(2009)
J Clin Oncol.
, vol.27
, pp. 3822-3829
-
-
Hess, G.1
-
5
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
-
6
-
-
84904724740
-
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Mayer, I. A. et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 32, 1202-1209 (2014).
-
(2014)
J Clin Oncol.
, vol.32
, pp. 1202-1209
-
-
Mayer, I.A.1
-
7
-
-
84894231823
-
Landscape of genomic alterations in cervical carcinomas
-
Ojesina, A. I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2014).
-
(2014)
Nature
, vol.506
, pp. 371-375
-
-
Ojesina, A.I.1
-
8
-
-
84924939973
-
Comprehensive Analysis of Targetable Oncogenic Mutations in Chinese Cervical Cancers
-
in press
-
Xiang, L. B. et al. Comprehensive Analysis of Targetable Oncogenic Mutations in Chinese Cervical Cancers. oncotarget (2015, in press).
-
Oncotarget
, vol.2015
-
-
Xiang, L.B.1
-
9
-
-
84863338519
-
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
-
Janku, F. et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 30, 777-782 (2012).
-
(2012)
J Clin Oncol.
, vol.30
, pp. 777-782
-
-
Janku, F.1
-
10
-
-
84917710610
-
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase i clinical experience
-
Hou, M. M. et al. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 5, 11168-11179 (2014).
-
(2014)
Oncotarget
, vol.5
, pp. 11168-11179
-
-
Hou, M.M.1
-
11
-
-
84871254065
-
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models
-
Spoerke, J. M. et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 18, 6771-6683 (2012).
-
(2012)
Clin Cancer Res.
, vol.18
, pp. 6771-6783
-
-
Spoerke, J.M.1
-
12
-
-
84914158009
-
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
-
Lopez, S. et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 135, 312-317 (2014).
-
(2014)
Gynecol Oncol.
, vol.135
, pp. 312-317
-
-
Lopez, S.1
-
13
-
-
84871968444
-
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in earlyphase clinical trials
-
Janku, F. et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in earlyphase clinical trials. Cancer Res. 73, 276-284 (2013).
-
(2013)
Cancer Res.
, vol.73
, pp. 276-284
-
-
Janku, F.1
-
14
-
-
84886094737
-
Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix
-
Wright, A. A. et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776-3783 (2013).
-
(2013)
Cancer
, vol.119
, pp. 3776-3783
-
-
Wright, A.A.1
-
15
-
-
84873719544
-
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
-
McIntyre, J. B. et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 128, 409-414 (2013).
-
(2013)
Gynecol Oncol.
, vol.128
, pp. 409-414
-
-
McIntyre, J.B.1
-
16
-
-
79960927451
-
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
-
Janku, F. et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6, e22769 (2011).
-
(2011)
PLoS One
, vol.6
, pp. e22769
-
-
Janku, F.1
-
17
-
-
64549095616
-
Mutation of PIK3CA: Possible risk factor for cervical carcinogenesis in older women
-
Cui, B. et al. Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol. 34, 409-416 (2009).
-
(2009)
Int J Oncol.
, vol.34
, pp. 409-416
-
-
Cui, B.1
-
18
-
-
38949121953
-
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
-
Miyake, T. et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 261, 120-126 (2008).
-
(2008)
Cancer Lett.
, vol.261
, pp. 120-126
-
-
Miyake, T.1
-
19
-
-
84907208070
-
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study
-
Sabine, V. S. et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32, 2951-2958 (2014).
-
(2014)
J Clin Oncol
, vol.32
, pp. 2951-2958
-
-
Sabine, V.S.1
-
20
-
-
79952713255
-
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas
-
Rudd, M. L. et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 17, 1331-1340 (2011).
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 1331-1340
-
-
Rudd, M.L.1
-
21
-
-
84941245510
-
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy + /- Cetuximab in Cervical Cancer Patients
-
de la Rochefordiere, A. et al. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy + /- Cetuximab in Cervical Cancer Patients. Clin Cancer Res 21, 2530-2537 (2015).
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2530-2537
-
-
De La Rochefordiere, A.1
-
22
-
-
0035872199
-
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation
-
Brognard, J. et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61, 3986-3997 (2001).
-
(2001)
Cancer Res
, vol.61
, pp. 3986-3997
-
-
Brognard, J.1
-
23
-
-
31544444486
-
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines
-
Lee, C. M. et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 12, 250-25 (2006).
-
(2006)
Clin Cancer Res
, vol.12
, pp. 250-325
-
-
Lee, C.M.1
-
24
-
-
84907208070
-
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study
-
Sabine, V. S. et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32, 2951-2958 (2014).
-
(2014)
J Clin Oncol
, vol.32
, pp. 2951-2958
-
-
Sabine, V.S.1
|